202 related articles for article (PubMed ID: 37014430)
1. Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection.
Cha DE; Yu AT; Khajoueinejad N; Gleeson E; Shaltiel T; Berger Y; Macfie R; Golas BJ; Sarpel U; Labow DM; Hiotis S; Cohen NA
World J Surg; 2023 Jul; 47(7):1801-1808. PubMed ID: 37014430
[TBL] [Abstract][Full Text] [Related]
2. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
3. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Rezaee N; Wu W; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Zheng L; Wolfgang CL; He J
Ann Surg; 2018 May; 267(5):936-945. PubMed ID: 28338509
[TBL] [Abstract][Full Text] [Related]
4. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma.
Crippa S; Pergolini I; Javed AA; Honselmann KC; Weiss MJ; Di Salvo F; Burkhart R; Zamboni G; Belfiori G; Ferrone CR; Rubini C; Yu J; Gasparini G; Qadan M; He J; Lillemoe KD; Castillo CF; Wolfgang CL; Falconi M
Ann Surg; 2022 Aug; 276(2):378-385. PubMed ID: 33086324
[TBL] [Abstract][Full Text] [Related]
5. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma.
Asakura Y; Toyama H; Ishida J; Asari S; Terai S; Shirakawa S; Yamashita H; Shimizu T; Ogura Y; Matsumoto I; Gon H; Tsugawa D; Komatsu S; Kuramitsu K; Yanagimoto H; Kido M; Ajiki T; Fukumoto T
Asian J Surg; 2023 Jan; 46(1):207-212. PubMed ID: 35370072
[TBL] [Abstract][Full Text] [Related]
7. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
8. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival.
Belfiori G; Crippa S; Francesca A; Pagnanelli M; Tamburrino D; Gasparini G; Partelli S; Andreasi V; Rubini C; Zamboni G; Falconi M
Ann Surg Oncol; 2021 Dec; 28(13):8249-8260. PubMed ID: 34258720
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
[TBL] [Abstract][Full Text] [Related]
11. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy.
Habib JR; Kinny-Köster B; Bou-Samra P; Alsaad R; Sereni E; Javed AA; Ding D; Cameron JL; Lafaro KJ; Burns WR; He J; Yu J; Wolfgang CL; Burkhart RA
Ann Surg; 2023 Jan; 277(1):151-158. PubMed ID: 33843794
[TBL] [Abstract][Full Text] [Related]
12. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition".
Belfiori G; Crippa S; Pagnanelli M; Gasparini G; Aleotti F; Camisa PR; Partelli S; Pecorelli N; De Stefano F; Schiavo Lena M; Palumbo D; Tamburrino D; Reni M; Falconi M
Ann Surg Oncol; 2024 Jun; 31(6):4084-4095. PubMed ID: 38459416
[TBL] [Abstract][Full Text] [Related]
13. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
15. Resected pancreatic adenocarcinoma: An Asian institution's experience.
Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
[TBL] [Abstract][Full Text] [Related]
16. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
17. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
[TBL] [Abstract][Full Text] [Related]
19. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma.
Shibata Y; Uemura K; Sumiyoshi T; Okada K; Otsuka H; Serikawa M; Ishii Y; Murakami Y; Arihiro K; Takahashi S
Langenbecks Arch Surg; 2023 Jul; 408(1):280. PubMed ID: 37458812
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]